T-Curx Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
T-Curx General Information
Description
Developer of personalized immunotherapies designed for targeted cancer treatment. The company utilizes virus-free transposon based genetic engineering and a modular car format to develop personalized immunotherapies, enabling the healthcare sector to access scalable and chemotherapy-free cancer treatments.
Contact Information
Website
www.t-curx.comCorporate Office
- Innovations- und Gründerzentrum Würzburg
- Friedrich-Bergius-Ring 15
- 97076 Wuerzburg
- Germany
Corporate Office
- Innovations- und Gründerzentrum Würzburg
- Friedrich-Bergius-Ring 15
- 97076 Wuerzburg
- Germany
T-Curx Timeline
T-Curx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Apr-2026 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series A) | 17-Dec-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 18-Sep-2017 | $10.4K | $10.4K | Completed | Clinical Trials - Phase 1 | |
| 1. University Spin-Out | Completed | Clinical Trials - Phase 1 |
T-Curx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T-Curx Patents
T-Curx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024394385-A1 | Method of producing leukocytes expressing artificial antigen receptors | Pending | 07-Dec-2023 | ||
| EP-4820066-A1 | Method of producing leukocytes expressing artificial antigen receptors | Pending | 07-Dec-2023 | ||
| WO-2025120230-A1 | Method of producing leukocytes expressing artificial antigen receptors | Inactive | 07-Dec-2023 | ||
| ES-2772709-T3 | Enhanced transposon system for gene delivery | Active | 16-Sep-2015 | ||
| EP-3350335-A1 | Improved transposon system for gene delivery | Active | 16-Sep-2015 | C12N15/90 |
T-Curx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
T-Curx Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arcas Ventures | Venture Capital | Minority | ||
| Bayern Kapital | Venture Capital | Minority | ||
| BiomedVC | Venture Capital | Minority | ||
| Highlight Capital | Venture Capital | Minority | ||
| i&i Biotech Fund | Venture Capital | Minority |
T-Curx Acquisitions (1)
T-Curx’s most recent deal was a Merger/Acquisition with Pantherna Therapeutics. The deal was made on 01-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pantherna Therapeutics | 01-Jun-2026 | Merger/Acquisition | Biotechnology |
T-Curx Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Pantherna Therapeutics | Hennigsdorf, Germany | 2017 |
T-Curx FAQs
-
When was T-Curx founded?
T-Curx was founded in 2017.
-
Where is T-Curx headquartered?
T-Curx is headquartered in Wuerzburg, Germany.
-
What is the size of T-Curx?
T-Curx has 1 total employees.
-
What industry is T-Curx in?
T-Curx’s primary industry is Drug Discovery.
-
Is T-Curx a private or public company?
T-Curx is a Private company.
-
What is T-Curx’s current revenue?
The current revenue for T-Curx is .
-
How much funding has T-Curx raised over time?
T-Curx has raised $20M.
-
Who are T-Curx’s investors?
Arcas Ventures, Bayern Kapital, BiomedVC, Highlight Capital, and i&i Biotech Fund are 5 of 6 investors who have invested in T-Curx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
